To look for such markers, we first analyzed the impact of mutation or overexpression of the major drivers that define the molecular subtypes of MM (BRAF, NRAS, NF1) [13,14,15,16], using information from the GDC-SKCM cohort. This evidence concerns the gene NF1 and Miyoshi myopathy.